Clinical

Dataset Information

0

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b


ABSTRACT: DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.

DISEASE(S): Colorectal Neoplasms,Pancreatic Neoplasms,Lung Neoplasms,Neoplasms,Solid Tumors

PROVIDER: 2177400 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2010-06-24 | E-GEOD-13808 | biostudies-arrayexpress
2010-01-13 | GSE17459 | GEO
2010-08-01 | GSE16677 | GEO
| PRJNA1142686 | ENA
2008-12-05 | GSE13808 | GEO
| PRJNA721696 | ENA
2013-01-17 | E-MTAB-1245 | biostudies-arrayexpress
| 2261433 | ecrin-mdr-crc
2007-05-01 | GSE6788 | GEO
2019-08-31 | GSE135008 | GEO